Chiesi USA, Inc.

What Chiesi USA, Inc. does

Chiesi USA, Inc. is the U.S. specialty pharmaceutical affiliate of privately-held Chiesi Farmaceutici S.p.A. (Parma, Italy), headquartered in Cary, North Carolina, and organized around three therapeutic franchises: U.S. AIR (respiratory), Rare Diseases, and U.S. CARE (neonatology and acute cardiology). Its commercial portfolio includes CLEVIPREX (clevidipine) and KENGREAL (cangrelor) in acute cardiology, CUROSURF (poractant alfa) in neonatology, FERRIPROX (deferiprone) and the pegunigalsidase alfa program in rare diseases, and — following the May 18, 2026 U.S. FDA approval — TRIMBOW, the company's first U.S. respiratory product, a single-inhaler triple fixed-dose combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrrolate (BDP/FF/G) delivered via a pressurized metered-dose inhaler (pMDI) with extrafine particle formulation for deep lung deposition. The pipeline is anchored by the Carbon Minimal Inhaler (CMI) next-generation low-GWP propellant program (€350M+ investment) and the inhaled PDE4 inhibitor tanimilast, with external innovation supplemented through partnerships with Serna Bio, Key2Brain, Arbor Biotechnologies, Aliada Therapeutics, Protalix, and Elgan Pharma.

The company operates a sales-led, specialty-pharmaceutical GTM model with dedicated U.S. AIR and U.S. CARE field sales forces led by VPs reporting to CEO Jon Zwinski, targeting hospital systems, GPOs, and office-based specialists in neonatology, pulmonology, and acute cardiology. Revenue mechanics are one-time branded specialty pharmaceutical product sales through commercial distribution channels, supplemented by copay assistance and expanded-access programs (Versaic platform). The U.S. business benefits from group-level R&D intensity of €885M in FY2025 (24.4% of €3.625B Group revenues, a Group record), with the U.S. identified as the parent Group's fastest-growing region at +23.5% actual / +28.9% at CER in FY2025.

Chiesi USA is structured as a Benefit Corporation in the U.S., has been a certified B Corporation since 2019 (recertified in 2025 with a verified score of 117.5), and maintains EcoVadis Platinum (88/100) and Great Place to Work certifications. There are no public shareholders; Chiesi USA is wholly owned by Chiesi Farmaceutici S.p.A., and operates under U.S.-only jurisdiction (Terms of Use restrict site to U.S. residents) governed by North Carolina law.

Name

Chiesi USA, Inc.

Legal name

Chiesi USA, Inc.

Website

https://chiesiusa.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Chiesi USA is the U.S. specialty pharmaceutical affiliate of Chiesi Farmaceutici S.p.A., commercializing branded therapies across respiratory (TRIMBOW), rare diseases (FERRIPROX), and acute care/neonatology (CLEVIPREX, KENGREAL, CUROSURF) to U.S. hospitals, specialists, and patient communities.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Asthma & Allergy-Related Pulmonary Care (HLAKANAD)

Keywords

• Specialty pharmaceuticals
• Respiratory therapeutics
• Neonatology treatments
• Acute cardiology drugs
• Rare disease therapies

Headquarters

HQ city

Cary

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Branded specialty pharmaceutical product sales: One-time product sales of branded FDA-approved therapeutics (CLEVIPREX, CUROSURF, KENGREAL, FERRIPROX, Bronchitol, TRIMBOW) to hospitals and office-based specialties. Distribution through commercial pharmaceutical supply chain with U.S. CARE and U.S. AIR sales forces.
2. Respiratory (Air) franchise revenues: Chiesi Group Air franchise (respiratory) reached €1.886 billion in FY2025, +3.9% at CER, driven by 15.8% growth in triple inhaled therapy (TRIMBOW-class products); partially offset by generic competition on legacy products.
3. Rare Disease franchise revenues: Chiesi Group Rare Disease franchise (e.g., FERRIPROX/deferiprone, pegunigalsidase alfa via Protalix partnership) generated €906 million in FY2025, +22.3% at CER, representing 50% of total Group growth.
4. Specialty Care (Care) franchise revenues: Chiesi Group Care franchise (neonatology products such as CUROSURF, acute cardiology products such as CLEVIPREX/KENGREAL) generated €904 million in FY2025, +13.3% at CER, with U.S. being the fastest-growing region.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels9 records

Core offering

Chiesi USA is a specialty pharmaceutical company that develops and commercializes branded FDA-approved therapeutics across three franchises: U.S. AIR (respiratory, anchored by TRIMBOW, the first U.S.-approved single-inhaler triple therapy for asthma), U.S. CARE (acute cardiology products CLEVIPREX and KENGREAL and neonatology product CUROSURF), and Chiesi Rare Diseases (FERRIPROX/deferiprone for transfusional iron overload and pegunigalsidase alfa via the Protalix partnership for Fabry disease). The company markets these therapeutics to U.S. hospitals and office-based specialty physicians via dedicated AIR and CARE business unit field-sales forces and a Medical Affairs team.

Product overview

Chiesi USA, Inc. is a specialty pharmaceutical company organized around three therapeutic franchises — AIR (respiratory), Rare Diseases, and CARE (special care / acute care, including neonatology) — rather than a single unified software product. Its marketed specialty pharmaceutical products include CLEVIPREX® (clevidipine injectable emulsion) and KENGREAL® (cangrelor for injection) in acute cardiology, CUROSURF® (poractant alfa intratracheal suspension) in neonatology, and TRIMBOW® (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate), the first FDA-approved respiratory product from the company's AIR franchise in the U.S. (approved May 18, 2026). The Chiesi Rare Diseases unit complements this portfolio with therapies for rare and ultra-rare disorders (including FERRIPROX®/deferiprone), and Chiesi USA's broader digital presence is supported by its website ecosystem (chiesiusa.com), online patient support, expanded access programs, and accessibility tooling rather than a single integrated software platform.

Differentiator

Problem solved

Functional benefit

Brands

• Chiesi Global Rare Diseases: Specialty division/subsidiary focused on developing and commercializing therapies for rare and ultra-rare diseases (e.g., FERRIPROX/deferiprone); maintains a separate branded website at chiesirarediseases.com.
• Chiesi AIR (U.S. AIR franchise)
• Chiesi CARE (U.S. CARE franchise)
• TRIMBOW
• KENGREAL
• CLEVIPREX
• CUROSURF

Products and services

• CLEVIPREX (clevidipine) Injectable Emulsion

Quantifiable outcome

• Chiesi Group FY2025 consolidated revenues of €3.625 billion (+8.2% at CER); U.S. region grew +23.5% at actual rates / +28.9% at CER (fastest-growing region)
• +4 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature4 records

Partnerships

18 partnerships are on record, tiered minor, core and flagship.

• Allergy & Asthma NetworkminorGTM or Marketing Partner · 18 May 2026Disease-awareness advocacy partnership; CEO Lynda Mitchell quoted in support of TRIMBOW FDA approval, emphasizing access, cost of care, and unmet needs in asthma.
• Baylor College of Medicine / Ben Taub Hospital (Nicola Hanania MD, MS)minorOthers · 18 May 2026Clinical KOL partnership; Dr. Nicola Hanania (Director, Airways Clinical Research Center at Baylor College of Medicine; Chief, Section of Pulmonary, Critical Care and Sleep Medicine, Ben Taub Hospital) provided clinical quote in support of TRIMBOW FDA approval.
• PODD (Partnership Opportunities in Drug Delivery) / The Conference ForumminorGTM or Marketing Partner · 26 February 2026Chiesi USA participated in PODD Drug Delivery 2025 webinar alongside AstraZeneca, Eli Lilly, Pfizer, and Bristol Myers Squibb, discussing strategic considerations for evaluating and structuring partnerships around drug delivery technologies. PODD 2026 Conference scheduled for October 29-30 at The Sheraton Boston.
• Asthma and Allergy Foundation of America (AAFA)minorGTM or Marketing Partner · 15 October 2025Disease-awareness advocacy partnership; AAFA President and CEO Kenneth Mendez provided quote in support of Chiesi's TRIMBOW NDA acceptance, citing the 28 million Americans with asthma and the need for expanded treatment options.
• Serna BiocoreStrategic or Co-development Partner · 24 July 2025Strategic collaboration with Chiesi Group to discover and develop RNA-targeted small molecules for respiratory diseases; announced 24 July 2025 as part of Chiesi's expanded respiratory innovation platform.
• Plug and PlaycoreStrategic or Co-development Partner · 16 July 2025Joint call for innovative solutions to improve respiratory care in the United States, leveraging Plug and Play's innovation platform to identify and support novel technologies and approaches addressing respiratory health challenges. Announced 16 July 2025.
• Elgan PharmacoreStrategic or Co-development Partner · 5 June 2025Joint development of ELGN-2112 for treatment of intestinal malabsorption in preterm infants; first participating infants dosed in Phase 3 study announced 5 June 2025. Aligns with Chiesi's CARE franchise focus on neonatology.
• Key2BraincoreStrategic or Co-development Partner · 1 January 2025Strategic partnership to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD); announced in 2025 as part of Chiesi Group's rare disease expansion.
• Arbor BiotechnologiescoreStrategic or Co-development Partner · 1 January 2025Partnership to develop a clinical-stage gene-editing program and access to broader platform capabilities for rare diseases; signed in 2025.
• Aliada TherapeuticscoreStrategic or Co-development Partner · 1 January 2025Strategic partnership to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD); signed in 2025.
• American Thoracic Society (ATS)coreGTM or Marketing Partner · 16 May 2024Chiesi is the largest supporter and Sapphire-level sponsor of the annual ATS Research Program Benefit; presented eight abstracts at ATS 2024 International Conference in San Diego and sponsors a one-year research grant for a respiratory disease researcher.
• Smith AndersonminorImplementation/ SI/ Consulting Partner · 12 June 2023Chiesi USA partners with Smith Anderson (law firm) to host a 1L Excellence in Diversity Fellow each summer, supporting legal profession diversity initiatives.
• ParentalyminorOthers · 1 January 2023Vendor/partnership for pre- and post-leave support programs for Chiesi USA employees and managers as part of parental leave benefits; supports Global Parenthood Guidelines including flexible work, training for new parents, equitable and extended parental leave (four months fully paid plus two additional months for birthing parents).
• Chiesi Farmaceutici S.p.A. (parent company)flagshipStrategic or Co-development Partner · 1 January 2023Chiesi USA is a wholly owned subsidiary of Chiesi Farmaceutici S.p.A., headquartered in Parma, Italy; parent provides global R&D, supply chain, and strategic direction including the Carbon Minimal Inhaler program and clinical pipeline that ultimately drive U.S. launches.
• Durham BullsminorGTM or Marketing Partner · 3 October 2022Chiesi USA partners with Durham Bulls to donate funds ($15,000 to three Triangle nonprofits in October 2022; nearly $15,000 in October 2021) through community engagement activations.
• Protalix BioTherapeuticscoreStrategic or Co-development Partner · 1 January 2021Long-running co-development partnership with Chiesi Global Rare Diseases for pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease; Phase III BALANCE, BRIDGE, and BRIGHT clinical trials; multiple regulatory updates and Complete Response Letters from FDA (April 2021).
• ASHP FoundationminorGTM or Marketing Partner · 1 January 2021Chiesi USA sponsors ASHP Foundation's Pharmacy Leadership Scholars Program and ASHP Advantage initiative supporting Pharmacy Technician Recruitment and Retention; Chiesi USA CEO appointed to ASHP Foundation Board of Directors in July 2023.
• March of Dimes Eastern North CarolinaminorGTM or Marketing Partner · 17 November 2020Chiesi USA supports March of Dimes Eastern North Carolina in observance of Prematurity Awareness Month, aligning with its neonatology-focused CARE franchise and CUROSURF product portfolio.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sanofi: Sanofi is a major respiratory player via Dupixent (dupilumab, co-developed with Regeneron), the leading biologic for severe asthma and atopic conditions in the U.S. — directly competitive to inhaled TRIMBOW for severe uncontrolled asthma patients. Sanofi also has significant rare-disease (Genzyme) and specialty-care franchises.
• Novartis: Novartis operates a respiratory portfolio (Enerzair in the SITT category globally) and has a meaningful rare-disease franchise. Novartis's global specialty pharma model and recent restructuring make it a broad incumbent comparable to Chiesi Group's three-franchise approach.
• Pfizer: Pfizer is a broad-incumbent pharma with a respiratory franchise and a significant rare-disease presence post-Seagen acquisition. Pfizer's specialty hospital sales infrastructure and U.S. field force overlap operationally with Chiesi USA's CARE business unit.
• Regeneron Pharmaceuticals: Regeneron co-commercialises Dupixent with Sanofi as the leading U.S. severe asthma biologic. Regeneron's specialty/biologic commercial model, KOL engagement, and payer negotiation approach for severe asthma overlap with Chiesi USA's specialty respiratory strategy.

Direct peers

• AstraZeneca: AstraZeneca markets Breztri Aerosphere (budesonide/glycopyrrolate/formoterol), the second FDA-approved SITT for COPD and a direct U.S. competitor to TRIMBOW. AstraZeneca also has a major rare-disease franchise via Alexion (acquired 2021) and significant respiratory biologics (Tezspire, Fasenra).
• Boehringer Ingelheim: Boehringer Ingelheim markets Spiriva (tiotropium), a leading LAMA in U.S. respiratory, plus Stiolto Respimat as a LAMA/LABA. As an established respiratory pharma with broad portfolio and rare-disease focus, Boehringer is a direct competitor in the same hospital/specialty HCP channel Chiesi USA targets.
• Vertex Pharmaceuticals: Vertex Pharmaceuticals markets Trikafta/Kaftrio for cystic fibrosis, the dominant CF therapy in the U.S. — competing with Chiesi's Bronchitol (mannitol) in the same CF pulmonary-function use case. Vertex's specialty-pharma commercial model and U.S. focus are structurally comparable to Chiesi USA's.
• GlaxoSmithKline: GSK markets Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the leading U.S. single-inhaler triple therapy (SITT) and Chiesi TRIMBOW's primary direct competitor in U.S. asthma/COPD maintenance. GSK also has a broader respiratory franchise (Advair, Breo, Anoro) and a rare-disease portfolio via its Vir partnership.
• Teva Pharmaceutical Industries: Teva is a major U.S. respiratory player with ProAir, Qvar, and generic ICS/LABA products, competing head-to-head with TRIMBOW in U.S. asthma maintenance. Teva also has a specialty/hospital channel for rare-disease and CNS therapies comparable to Chiesi USA's CARE franchise.

Emerging players

• Protalix BioTherapeutics: Protalix is Chiesi's co-development partner for pegunigalsidase alfa (PRX-102) in Fabry disease, a key asset within Chiesi USA's Rare Disease franchise. As the upstream development partner and biologics manufacturer, Protalix is operationally entwined with Chiesi USA's rare-disease pipeline value.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/37210
• Instagraminstagram.com/lifeinchiesusa

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chiesi USA, Inc.